Chemours Q3 2023: Adjusted EPS $0.63; cuts FY Adj. EBITDA guidance to $1.025-1.075B

Chemours Co

2023-Q3 EPS reported -$1.42 revenue$4,666,000,000

Net sales $1.5B (-16% YoY); Net income $20M ($0.13 EPS); Adjusted net income $96M ($0.63 adj. EPS).
Adjusted EBITDA $247M; FY 2023 guidance lowered ~8% midpoint to $1.025-1.075B.
Launched TT Transformation Plan targeting ~$100M run-rate cost savings starting 2024.
Board approved Q3 dividend of $0.25/share; sale of Glycolic Acid business closed for $138M net cash.
Weakness in TT and APM Advanced Materials driven by macroeconomic environment.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Chemours Co reported third quarter 2023 results: revenue $1.5 billion, net income $20 million, EPS $0.13. Guidance lowered.

Period: third quarter 2023
Revenue: $1.5 billion
Net income: $20 million
EPS: $0.13
Guidance: lowered
Result: reported results

Exact text from the filing

(“APM”), today announced its financial results for the third quarter 2023, and Titanium Technologies Transformation Plan. Third Quarter 2023 Results & Highlights • Net Sales of $1.5 billion • Net Income of $20 million with EPS 1 of $0.13 • Adjusted Net Income 2 of $96 million with Adjusted EPS 2 of $0.63 • Adjusted EBITDA 2 of $247 million and Adjusted Free Cash

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Chemours Co filing history →

Source: SEC EDGAR

accession 0000950170-23-055626

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.